Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713283 | 1.00 | CYP2C9 (0.48) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL12713285 | 1.00 | CYP2C9 (0.48) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL2797496 | 1.00 | CYP2C9 (0.48) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL29351668 | 0.83 | USP2 (0.50) | CYP2C9CYP3A4USP2ALOX15HSD17B10 | |
| SCHEMBL44904 | 0.83 | HDAC8 (0.58) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL29350881 | 0.83 | HDAC8 (0.58) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL44905 | 0.83 | HDAC8 (0.58) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL668470 | 0.83 | USP2 (0.50) | CYP2C9CYP3A4USP2ALOX15HSD17B10 | |
| SCHEMBL1613174 | 0.83 | HDAC8 (0.58) | CYP2C9CYP3A4CYP1A2USP2ALOX15 | |
| SCHEMBL668469 | 0.83 | USP2 (0.50) | CYP2C9CYP3A4USP2ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849018-B | Piperazine derivatives | 安斯泰来制药株式会社 | 2021-02-23 | — | — | CN | disclosed |
| EP-3333165-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
| EP-3333165-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2018-06-13 | — | — | EP | disclosed |
| CN-107849018-A | Bridged piperazine derivatives | 安斯泰来制药株式会社 | 2018-03-27 | — | — | CN | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | CYP2C9 4786/4885CYP3A4 2581/4885CYP1A2 3954/4885 |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | CYP2C9 2245/4885CYP3A4 2689/4885CYP1A2 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.